Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Advanced Proteome Therapeutics Corporation APTCF


Primary Symbol: V.APC.H

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.

TSXV:APC.H - Post Discussion

View:
Post by Goldnboy1 on Apr 08, 2021 12:56am

So it begins...

Been telling investors since mid 2020 that this stock has a bright future ahead of it. 

This is just the beginning!! 

Re-Rate fully engaged!!

Comment by mhaimillionaire on Apr 08, 2021 4:48am
According to McMullin, "The outstanding market response we experienced in Q4 of 2020 reconfirmed the strategy that brought FDS and Amplicare together at the right time to support pharmacies' financial, data, and communication needs, especially during this high-demand, challenging time. We are grateful for all they do in their communities and their continued support." This was great.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities